With regard to the genomic classification of melanomas, there was no propensity for BRAF, NRAS, or NF1 mutations in any of the clinical subgroups in this study, although some authors suggest that BRAF mutations are associated with the nevogenic pathway of melanoma genesis and that NF1, ROS1, GNA11, and RAC1 mutations are associated with CSD-associated melanomas [34]. This evidence concerns the gene NF1 and melanoma.